Subthalamic nucleus-deep brain stimulation for early motor complications in Parkinson's disease-the EARLYSTIM trial: Early is not always better

Movement Disorders

Volumn 29, Issue 14, 2014, Pages 1751-1756

  Mestre, Tiago A ^a,b   Espay, Alberto J ^c   Marras, Connie ^a   Eckman, Mark H ^c   Pollak, Pierre ^d   Lang, Anthony E ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF CINCINNATI   (United States)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Dyskinesia; EARLYSTIM; Health economics; Motor complications; Parkinson's disease; Patient expectation; Subthalamic nucleus the brain stimulation

Indexed keywords

BRAIN DEPTH STIMULATION; CLINICAL TRIAL (TOPIC); ELECTROSTIMULATION THERAPY; HUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; SUBTHALAMIC NUCLEUS; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DEEP BRAIN STIMULATION; ELECTRIC STIMULATION THERAPY; HUMANS; PARKINSON DISEASE; SUBTHALAMIC NUCLEUS; TREATMENT OUTCOME;

EID: 84918593475     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26024     Document Type: Article

References (27)

1. Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013;368:610-622.
2. Woopen C, Pauls KA, Koy A, Moro E, Timmermann L. Early application of deep brain stimulation: clinical and ethical aspects. Prog Neurobiol 2013;110:74-88.
3. Deuschl G, Agid Y. Subthalamic neurostimulation for Parkinson's disease with early fluctuations: balancing the risks and benefits. Lancet Neurol 2013;12:1025-1034.
4. Hariz M. Early surgery for Parkinson's disease? Maybe, but not just yet. Lancet Neurol 2013;12:938-939.
5. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006;355:896-908.
6. Kleiner-Fisman G, Herzog J, Fisman DN, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 2006;21(Suppl 14):S290-S304.
7. Schapira AH, Schrag A. Parkinson disease: Parkinson disease clinical subtypes and their implications. Nat Rev Neurol 2011;7:247-248.
8. Valldeoriola F, Morsi O, Tolosa E, Rumia J, Marti MJ, Martinez-Martin P. Prospective comparative trial on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease. Mov Disord 2007;22:2183-2191.
9. Eggington S, Valldeoriola F, Chaudhuri KR, Ashkan K, Annoni E, Deuschl G. The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson's disease. J Neurol 2014;261:106-116.
10. Meissner W, Schreiter D, Volkmann J, et al. Deep brain stimulation in late stage Parkinson's disease: a retrospective cost analysis in Germany. J Neurol 2005;252:218-223.
11. Dams J, Siebert U, Bornschein B, et al. Cost-effectiveness of deep brain stimulation in patients with Parkinson's disease. Mov Disord 2013;28:763-771.
12. Espay AJ, Vaughan JE, Marras C, Fowler R, Eckman MH. Early versus delayed bilateral subthalamic deep brain stimulation for Parkinson's disease: a decision analysis. Mov Disord 2010;25:1456-1463.
13. Goetz CG, Wuu J, McDermott MP, et al. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord 2008;23:690-699.
14. Marks WJ, Jr., Bartus RT, Siffert J, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010;9:1164-1172.
15. Gross RE, Watts RL, Hauser RA, et al. Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2011;10:509-519.
16. McRae C, Cherin E, Yamazaki TG, et al. Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial. Arch Gen Psychiatry 2004;61:412-420.
17. Mercado R, Constantoyannis C, Mandat T, et al. Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation. Mov Disord 2006;21:1457-1461.
18. Pollo A, Torre E, Lopiano L, et al. Expectation modulates the response to subthalamic nucleus stimulation in Parkinsonian patients. Neuroreport 2002;13:1383-1386.
19. de la Fuente-Fernández R. Uncovering the hidden placebo effect in deep-brain stimulation for Parkinson's disease. Parkinsonism Relat Disord 2004;10:125-127.
20. Mestre TA, Shah P, Marras C, Tomlinson G, Lang AE. Another face of placebo: The lessebo effect in Parkinson disease: meta-analyses. Neurology 2014;82:1402-1409.
21. Maier F, Lewis CJ, Horstkoetter N, et al. Patients' expectations of deep brain stimulation, and subjective perceived outcome related to clinical measures in Parkinson's disease: a mixed-method approach. J Neurol Neurosurg Psychiatry 2013;84:1273-1281.
22. Weiner WJ, Factor SA, Jankovic J, et al. The long-term safety and efficacy of pramipexole in advanced Parkinson's disease. Parkinsonism Relat Disord 2001;7:115-120.
23. Moller JC, Oertel WH, Koster J, Pezzoli G, Provinciali L. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord 2005;20:602-610.
24. Lewitt PA, Boroojerdi B, Surmann E, Poewe W; SP716 Study Group; SP715 Study Group. Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER. J Neural Transm 2013;120:1069-1081.
25. Hilker R, Portman AT, Voges J, et al. Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry 2005;76:1217-1221.
26. Lang AE, Houeto JL, Krack P, et al. Deep brain stimulation: preoperative issues. Mov Disord 2006;21(Suppl 14):S171-S196.
27. Bronstein JM, Tagliati M, Alterman RL, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol 2011;68:165.